Navigating your path to globalization: Untangling the regulatory maze of the Advanced Therapies supply chain
Discover how Cryoport Systems can help you navigate EMEA regulations and manage the supply chain complexities for advanced therapies.
- Latest Posts
News and Trends 27 Aug 2024
Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?
As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond.
Podcast 23 Aug 2024
New German biotech spins out to develop radiotherapeutics
While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company
Best in Biotech 22 Aug 2024
Seven companies transforming the biotech industry in Italy
Delve into Italy’s biotech landscape with seven companies that are leading the charge in the European country.
In Depth 21 Aug 2024
The promise of antisense oligonucleotides in precision medicine
Find out all about antisense oligonucleotides, which have gained a lot of popularity in recent years and could treat numerous diseases.
News and Trends 20 Aug 2024
Fighting mpox: promising vaccines to watch
As Bavarian Nordic ramps up production of the only marketed mpox vaccine, a few clinical trials are underway to combat the outbreak.
ADVERTISEMENT
ADVERTISEMENT
Podcast 16 Aug 2024
Challenging the European biotech funding status quo
Explore the latest trends in biotech investments and funding strategies in Europe with insights from 4BIO Capital’s Dima Kuzmin.
Best in Biotech 15 Aug 2024
10 neuroscience biotech companies you should know about
Learn more about nine of the top neuroscience biotech companies looking to develop treatments for difficult-to-treat neurological conditions.
News and Trends 14 Aug 2024
CAR-T drugs and parkinsonism: a cause for concern?
CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt.
News and Trends 13 Aug 2024
Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry?
Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug.
In Depth 9 Aug 2024
The therapeutic potential of circular RNA: Could it soon trump mRNA technology?
Find out about circular RNA, an emerging technology that could hold a lot of promise for next-generation vaccines and gene therapies.
Podcast 9 Aug 2024
Rebroadcast: Epigenetic editing – the power of CRISPR without cutting DNA
This week, we discuss epigenetic editing, why it’s reversible, treating FSHD and other conditions, with Epic Bio founder, Dr Stanley Qi.
ADVERTISEMENT
